Introduction
The demand for symptom relief, reduced side effects of medical strategies, and improved patients' The EORTC QLQ-C30, which is applicable to the general cancer population, has become the most widely used HRQOL questionnaire in cancer RCTs during the last two decades (3) (4) (5) (6) (7) .
This review arises from the activities of the EORTC PROBE initiative, which aimed to develop a user-ready HRQOL database of scores collected on the QLQ-C30, and to use it to investigate general research questions common across different cancer types. Collecting data from closed The EORTC Patient-Reported Outcomes and Behavioural Evidence Initiative Page 5 of 26 international oncology RCTs that informed clinical practice over the years (8) has been challenging.
HRQOL data are collected and analyzed trial by trial and published either together with clinical data or separately, to measure the impact of cancer and its treatment on patients' HRQOL. This leads inevitably to a fragmented body of evidence, often with inconsistent methods of data collection, analysis and reporting. Construction of a meta-dataset, which pools data from different cancer clinical trials across different patient populations (e.g., lung, breast, melanoma) or disease stages (e.g., primary versus advanced), can give a more comprehensive view of HRQOL in oncology. Moreover, it allows the application of analytical techniques demanding large sample sizes in a field where data collection is often very restricted and expensive. PROBE undertook the challenge to merge international RCTs and make meaningful analyses of these data with the support of the PROBE international advisory board (composed of medical, clinical, statistical, psychological and other experts across different fields) which scrutinized the analyses and their interpretation and advised on the overall management of the research initiative.
PROBE had a specific mandate to focus on the practical application of HRQOL in clinical trials research. The research objectives identified by the PROBE team and reviewed in this article were therefore to assess the prognostic value of HRQOL for survival, to compare clinicians' and patients' HRQOL assessment for their prognostic value for overall survival (OS), to explore whether QLQ-C30 domains cluster, to investigate minimally important differences (MID) for interpreting HRQOL scores from the QLQ-C30, and to examine the effect of completion-time windows on HRQOL outcomes (Figure 1 ).
INSERT FIGURE 1
The 
Statistical Analysis
The different analysis techniques and statistical methods used in the reviewed research projects are fully reported within the references of the previously conducted analyses (9) (10) (11) (12) (13) (14) (15) (16) (17) .
Results

HRQOL Adds Prognostic Value Beyond Clinical Information
One of the key questions cancer patients ask their clinicians when diagnosed with cancer is 'How The question then arose whether different HRQOL domains are prognostic for survival for different cancer sites. By using a dataset of 7,417 patients who completed the QLQ-C30 before randomization, Quinten et al. (11) found that at least one HRQOL domain provided prognostic information for each cancer site, alongside clinical and socio-demographic variables (Table 1) , although which domain provided the greatest prognostic power differed by cancer type.
INSERT TABLE 1
A universal HRQOL domain with valid prognostic impact across cancer site could not be identified. Physical functioning and nausea/vomiting were found to provide unique prognostic information in several but not all cancer sites.
By using longitudinal HRQOL data from a single advanced non-small-cell lung cancer trial (N=391) we investigated whether changes in HRQOL scores over time during chemotherapy treatment can be prognostic of survival in addition to clinical characteristics. It was found that a 10-point improvement in pain (from baseline to end of cycle 1) or social function (from baseline to end of cycle 2) was associated with a lower risk of death (12) . Meanwhile pain, physical function and dysphagia (single item of lung cancer specific module QLQ-LC13 assessing treatment related side effects (18)) were important baseline prognostic factors.
These studies provided further evidence that HRQOL can provide prognostic information beyond clinical measures, improve prognostic accuracy in cancer clinical trials, and yield informative factors to stratify and monitor patients for supportive interventions but that the actual, prognostic HRQOL domains may vary across disease sites (9-12).
Patients' Self-Reports along with Clinicians' Scores Improve Survival Prediction
Typically, to estimate overall survival, clinician evaluation of symptoms is incorporated into a model of prognosis. When considering treatment options, a reliable survival prognosis is a valuable tool to make an informed decision. The clinician scoring of symptoms has conventionally been used. However, the weak agreement between clinician and patient reporting of symptoms is notable (19) . In this PROBE analysis, the relative information gained in estimating survival when including baseline information of patient-reported symptoms was compared to that reported by clinicians (assessed using Common Terminology Criteria for Adverse Events), across various disease sites, stages and treatments. We found that for the six symptoms assessed at baselinepain, fatigue, vomiting, nausea, diarrhea, and constipation -the models that considered both patient and clinician scores gained significantly more prognostic OS accuracy: namely fatigue (P<.001), vomiting (P=.01), nausea (P<.001), and constipation (P=.01), than models which considered clinician scores alone (13) . The results of this retrospective PROBE analysis were acknowledged by the American Society of Clinical Oncology's (ASCO) Annual Report on Progress Against Cancer as one among those with the greatest potential impact on patients' lives (20) , suggesting that adding patient-reported symptom scores to the traditional physician-based scoring system may result in a more accurate prognosis of survival.
Examining HRQOL Domain Clusters
Understanding the grouping between symptom and/or functioning domains may aid clinicians in managing the symptom burden experienced by patients, and may help policy-makers to develop psychosocial support plans. We attempted to identify how HRQOL domains cluster and which HRQOL indicators are linked to patients' perception of overall quality of life (14) . The results revealed physical (physical and role functioning, fatigue, pain), psychological (emotional and cognitive functioning, insomnia) and gastrointestinal clusters (nausea/vomiting, appetite loss) emerging from the overall dataset. Each cluster had high to moderate internal consistency ( = .84, .64 and .67 respectively), indicating that the included scales are associated. The same clusters were found in subgroups defined according to socio-demographic and clinical characteristics,
Page 10 of 26 while some differences emerged among cancer sites. The global health status/quality of life scale was found to be part of the physical cluster in the overall dataset. This result was consistent across different levels of disease severity, but divergent results were seen across some cancer sites. These findings suggest that HRQOL domains are interrelated and form clusters; however, clusters vary by disease. Identifying the mechanisms which define the relationships between HRQOL domains is important for appropriate problem management and the identification of populations that could benefit from receiving tailored psychosocial support and/or improved supportive care interventions.
Providing More Evidence-Based Data on Minimally Important Differences
MID refers to the smallest change or difference between HRQOL scores that is considered to be clinically relevant. This is an important notion with many implications, as it informs clinicians, patients, regulators and clinical trialists as to which changes in HRQOL scores are important. For example, MIDs may be used to assess the value of a health care intervention or to compare treatments, to make adjustments in health care policies or to inform a clinician's decision to apply an intervention in a given situation (21) . MIDs may also be useful in determining sample sizes in designing future RCTs. The methods commonly used to calculate MID are anchor-based or distribution-based (22) (23) (24) (25) . An example of the most widely used anchor-based approach was provided in the first estimation of MIDs for the QLQ-C30, which used the subjective significance questionnaire (21) to link changes in QLQ-C30 scores to patients' ratings of subjectively meaningful changes.
A PROBE analysis of two closed non-small-cell lung cancer (NSCLC) RCTs (26) (27) , demonstrated that MID estimates for improvement appeared larger than those for deterioration in QLQ-C30 (15) . The WHO performance status and weight change were used as clinical anchors.
When anchoring with WHO performance status, the MID estimates for improvement or deterioration respectively were: physical functioning: (9, 4), role functioning: (14, 5) 
HRQOL Completion-Time Windows -Does It Matter?
A key aspect in the design and analysis of HRQOL data is the timing of the assessments. In an appropriately designed clinical trial, the protocol will state exactly when the HRQOL assessments are scheduled, e.g., 1-3 days prior to each treatment cycle. However, deviations from these schedules are often encountered during the course of the trial as patients may not be able to complete the questionnaire at the scheduled time. Consequently analyses of HRQOL data frequently use 'completion-time windows' around the expected completion time (31) . A certain Page 12 of 26 number of days before and after the scheduled treatment cycle date may be allowed, so that all questionnaires completed within that period are assumed to belong to that particular cycle.
Such time intervals, rather than a single fixed visit, allow more flexibility in data collection, thereby minimizing missing data. The impact of these completion-time windows was explored, involving RCTs of different cancer treatments, e.g., radiotherapy, chemotherapy.
We examined whether the QLQ-C30 scores of cancer patients undergoing chemotherapy are affected by the specific time point before, during or after treatment at which the questionnaire is completed, and whether this could bias the overall treatment comparison analyses. Using linear mixed models for the analyses of longitudinal data (31), we found statistically significant differences (P<.05) for during and after treatment comparisons in these trials (17) . For all three closed RCTs, the longitudinal mixed models resulted in a better fit when the 'completion-time window' variable was included. However, differences were not sufficient to change treatment PROBE's contribution to clinical research was recognized when one PROBE publication was featured as a "notable advance" that successfully informed and changed clinical practice according to ASCO's annual report on progress against cancer, "Clinical Cancer Advances 2012" (16) . We continue to encourage collaboration at every level, and have raised these issues at the European Parliament, which has been very supportive of our initiative (32) .
PROBE investigated critical topics with a significant impact on future psychosocial care. Key outcomes were identified for improving the survival prognostication using HRQOL data, collected through the QLQ-C30. By exploring and identifying clusters of HRQOL problems, evidence of symptom interrelation was found which can benefit patients and lead to improvement of symptom management. The MID varied across brain and lung cancer patients indicating there is need for additional empirical investigation of MIDs. Last, it provided valuable evidence on the importance of using completion-time windows in the design of clinical trials and in the analysis of HRQOL outcomes. Yet, the variability of results and diversity of symptoms across cancer sites makes the application and generalization of the findings challenging. PROBE will undertake research to estimate and compare MIDs on the QLQ-C30 across various patient populations that will provide guidelines for general interpretation.
The
However, we must not gloss over several methodological and statistical challenges and problems that had to be overcome during the course of pooling HRQOL and clinical data to conduct these retrospective analyses. The lack of availability of common indicators important for a full investigation of the research question was a major challenge (e.g. disease stage, medical history).
Variability across clinical trials on many important components, like the timing of assessments, made merging data a complex task. To address these challenges we were forced to use complex methodological designs and techniques to account for heterogeneity (33) . Drop out and nonadherence with HRQOL assessments at follow-up limited the available HRQOL data and presented considerable missing data challenges. The various data management systems used by different clinical trials organizations made pooling time consuming.. Data privacy and ownership issues also made pooling difficult and, in some cases, precluded participation of interested researchers or groups. Equally challenging was the task of funding research dissemination via the most appropriate channels and media (i.e. conference organization, press releases etc.), to provide a greater understanding of HRQOL and anticancer treatment, and boost public and clinical awareness. Infrastructure barriers and the lack of specialized staff in cancer related HRQOL were other issues we had to overcome to ensure project sustainability. A limitation of our research relates to the disproportional representation of the study population due to the availability of large scale studies within certain cancer types (e.g. 3125 melanoma patients vs. 78 esophageal cancer patients; Figure 2 ). Another limitation is poor HRQOL compliance in cancer clinical trials and the lack of good longitudinal HRQOL data, which restricted our research mainly to baseline data.
Going forward, one way to overcome the challenges that the pooled datasets present would be the use of standardized core clinical trial datasets for outcome measures, standardized collection and coding and more clinical trial data sharing. Uniform publication guidelines (34) (35) will allow HRQOL data to be more consistently presented. Development of large-scale global collaborations such as the PROBE initiative has proven to be a valuable way of using existing data, and benefits both patients and society by improving clinical care and understanding cancer. Such a repository of data will prove useful for many years to come. An automated way of adding new trial data to enrich the HRQOL dataset will be developed by the EORTC with the support of our international collaborators. The growth of PROBE with ten newly closed and fully published EORTC RCTs and the inclusion of pharmaceutical clinical trial data will provide an even larger and ever-growing database. This will allow us to answer more complex and overarching questions on key topics in oncology, such as institutional compliance.
However, access to datasets and the merging of data is complex, with difficult processes; we need to be realistic about the challenges and expenditure. We invite other clinical trial researchers who have an interest in HRQOL research to work with us, join us, share data, and increase the pool of data, so many more important questions can be addressed and new questions can be developed.
In summary, we hope the PROBE initiative has shown that closed RCTs with HRQOL data can play an important role in the planning of future research, promote a better understanding of cancer care and the role of patient-reported HRQOL assessments (37) , and extend our knowledge of methodological issues in HRQOL assessment. This initiative has demonstrated the benefits of 
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